Clinical Trial

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-09-05.
Status change: Not Yet Recruiting → Recruiting 2024-10-14
Trial Details
NCT Number NCT05043688
Lead Sponsor Zhigang Li
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Resectable Esophageal Squamous Cell Carcinoma
Enrollment 426 participants
Start Date 2021-09-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-17